NCT00807677View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaChronic Lymphocytic LeukemiaMultiple MyelomaWaldenstrom's MacroglobulinemiaMyelodysplastic SyndromePhiladelphia Chromosome-negative CMLMyeloid MetaplasiaMyelofibrosisAdvanced PolycythemiaNon-Hodgkins Lymphoma
Interventions
DRUG

TAK-901

TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY